<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893371</url>
  </required_header>
  <id_info>
    <org_study_id>16-243</org_study_id>
    <secondary_id>CER-1507-31607</secondary_id>
    <nct_id>NCT02893371</nct_id>
  </id_info>
  <brief_title>Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies</brief_title>
  <official_title>Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montana State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Alliance on Mental Illness Montana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CGStat LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Risk Benefit Statistics LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Alliance on Mental Illness New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Alliance on Mental Illness Westside Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this retrospective observational study is to compare commonly prescribed&#xD;
      bipolar disorder medications for their impact on: (1) hospitalization; (2) suicide attempts&#xD;
      and self-harm; and (3) risk of drug-induced adverse effects such as kidney disease and&#xD;
      diabetes mellitus. In addition, the investigators will examine heterogeneity of treatment&#xD;
      effect by co-morbidity within pediatric, adult, and elderly sub-populations. Patient focus&#xD;
      groups are convened to elicit additional questions and provide feedback on results.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Funded by PCORI, the objective of this retrospective observational study is to perform&#xD;
      several safety and effectiveness comparisons on commonly prescribed bipolar disorder&#xD;
      medications, engaging patient focus groups in generating additional questions and&#xD;
      interpreting results.&#xD;
&#xD;
      The study will be a retrospective cohort study conducted with administrative claims data from&#xD;
      the Truven MarketScan Commerical Claims and Encounters and Medicare database from 2010-2016.&#xD;
&#xD;
      The database contains approximately 140 million patients within the US population in every&#xD;
      state and nearly every county in the nation, across all ages, ethnicities and socioeconomic&#xD;
      categories, including privately insured, and Medicare patients. The study will focus on&#xD;
      approximately one million patients with two or more diagnoses of bipolar disorder in the&#xD;
      claims records according to ICD-9 and/or ICD-10 coding.&#xD;
&#xD;
      The treatments that will be compared are lithium carbonate; first generation antipsychotics:&#xD;
      haloperidol and perphenazine; second generation antipsychotics: clozapine, risperidone,&#xD;
      olanzapine, aripiprazole, quetiapine, ziprasidone, asenapine, lurasidone, and paliperidone;&#xD;
      mood stabilizing anticonvulsants: valproate, lamotrigine, carbamazepine, and oxcarbazepine;&#xD;
      antidepressants: mirtazapine, bupropion, desvenlafaxine, duloxetine, venlafaxine, citalopram,&#xD;
      escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, vilazodone, and doxepin.&#xD;
&#xD;
      The investigators will perform cross-sectional and survival based analysis using regression,&#xD;
      propensity scoring, and local control to perform bias-corrected comparisons of the above&#xD;
      treatments for for their impact on: (1) hospitalization; (2) suicide attempts and self-harm;&#xD;
      and (3) risk of drug-induced adverse effects such as kidney disease and diabetes mellitus. In&#xD;
      addition, the investigators will examine heterogeneity of treatment effect by co-morbidity&#xD;
      within pediatric, adult, and elderly sub-populations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of hospitalization</measure>
    <time_frame>0-7 years</time_frame>
    <description>For each treatment, assess the risk of rehospitalization within 30-days after hospitalization for a mood episode. For each treatment, assess the cumulative incidence of hospitalization for a mood episode any time after commencing treatment, accounting for the competing risk of ending treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of suicide and self-harm</measure>
    <time_frame>0-7 years</time_frame>
    <description>For each treatment, assess the cumulative risk of a second suicide or self-harm event after diagnosis of a first event, accounting for the competing risk of ending treatment. Self-harm includes injuries of unknown intent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney disease</measure>
    <time_frame>0-7 years</time_frame>
    <description>For each treatment, assess time to first instance of renal condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes mellitus</measure>
    <time_frame>0-7 years</time_frame>
    <description>For each treatment, assess time to diagnosis of diabetes mellitus</description>
  </secondary_outcome>
  <enrollment type="Actual">1037352</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Carbonate</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Lithobid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Lamictal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Depakote</other_name>
    <other_name>Valproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxcarbazepine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Trileptal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Equetro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Geodon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine / Olanzapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Symbyax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Haldol Decanoate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perphenazine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Trilafon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Clozaril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Saphris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Latuda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Invega</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Remeron</other_name>
    <other_name>Remeronsoltab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Zyban</other_name>
    <other_name>Aplenzin</other_name>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Pristiq</other_name>
    <other_name>Desfax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Cymbalta</other_name>
    <other_name>Irenka</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Effexor XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Celexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Prozac</other_name>
    <other_name>Sarafem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Faverin</other_name>
    <other_name>Fevarin</other_name>
    <other_name>Floxyfral</other_name>
    <other_name>Dumyrox</other_name>
    <other_name>Luvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Paxil</other_name>
    <other_name>Seroxat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilazodone</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Viibryd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxepin</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Sinequan</other_name>
    <other_name>Silenor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of individuals with bipolar disorder enrolled with private&#xD;
        insurers or with Medicare across the United States, as captured in the Truven Health&#xD;
        Analytics MarketScan databases. The time period of data coverage is 2003-2016.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Two or more instances of bipolar disorder diagnoses within administrative claims&#xD;
             records&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with less than 1 year of history in the database&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe G Lambert, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christophe G Lambert</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pcori.org/research-results/2016/longitudinal-comparative-effectiveness-bipolar-disorder-therapies</url>
    <description>Announcement of PCORI project award.</description>
  </link>
  <link>
    <url>https://www.pcori.org/research-results/2016/comparing-medicines-long-term-treatment-bipolar-disorder</url>
    <description>Results summary</description>
  </link>
  <results_reference>
    <citation>Nestsiarovich A, Hurwitz NG, Nelson SJ, Crisanti AS, Kerner B, Kuntz MJ, Smith AN, Volesky E, Schroeter QL, DeShaw JL, Young SS, Obenchain RL, Krall RL, Jordan K, Fawcett J, Tohen M, Perkins DJ, Lambert CG. Systemic challenges in bipolar disorder management: A patient-centered approach. Bipolar Disord. 2017 Dec;19(8):676-688. doi: 10.1111/bdi.12547. Epub 2017 Sep 13.</citation>
    <PMID>28901625</PMID>
  </results_reference>
  <results_reference>
    <citation>Nestsiarovich A, Mazurie AJ, Hurwitz NG, Kerner B, Nelson SJ, Crisanti AS, Tohen M, Krall RL, Perkins DJ, Lambert CG. Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders. Bipolar Disord. 2018 Dec;20(8):761-771. doi: 10.1111/bdi.12665. Epub 2018 Jun 19.</citation>
    <PMID>29920885</PMID>
  </results_reference>
  <results_reference>
    <citation>Nestsiarovich A, Kerner B, Mazurie AJ, Cannon DC, Hurwitz NG, Zhu Y, Nelson SJ, Oprea TI, Unruh ML, Crisanti AS, Tohen M, Perkins DJ, Lambert CG. Comparison of 71 bipolar disorder pharmacotherapies for kidney disorder risk: The potential hazards of polypharmacy. J Affect Disord. 2019 Jun 1;252:201-211. doi: 10.1016/j.jad.2019.04.009. Epub 2019 Apr 8.</citation>
    <PMID>30986735</PMID>
  </results_reference>
  <results_reference>
    <citation>Kerner B, Crisanti AS, DeShaw JL, Ho JG, Jordan K, Krall RL, Kuntz MJ, Mazurie AJ, Nestsiarovich A, Perkins DJ, Schroeter QL, Smith AN, Tohen M, Volesky E, Zhu Y, Lambert CG. Preferences of Information Dissemination on Treatment for Bipolar Disorder: Patient-Centered Focus Group Study. JMIR Ment Health. 2019 Jun 25;6(6):e12848. doi: 10.2196/12848.</citation>
    <PMID>31237566</PMID>
  </results_reference>
  <results_reference>
    <citation>Kumar P, Nestsiarovich A, Nelson SJ, Kerner B, Perkins DJ, Lambert CG. Imputation and characterization of uncoded self-harm in major mental illness using machine learning. J Am Med Inform Assoc. 2020 Jan 1;27(1):136-146. doi: 10.1093/jamia/ocz173.</citation>
    <PMID>31651956</PMID>
  </results_reference>
  <results_reference>
    <citation>Nestsiarovich A, Kerner B, Mazurie AJ, Cannon DC, Hurwitz NG, Zhu Y, Nelson SJ, Oprea TI, Crisanti AS, Tohen M, Perkins DJ, Lambert CG. Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. Psychoneuroendocrinology. 2020 Feb;112:104511. doi: 10.1016/j.psyneuen.2019.104511. Epub 2019 Nov 9.</citation>
    <PMID>31744781</PMID>
  </results_reference>
  <results_reference>
    <citation>Nestsiarovich A, Kumar P, Lauve NR, Hurwitz NG, Mazurie AJ, Cannon DC, Zhu Y, Nelson SJ, Crisanti AS, Kerner B, Tohen M, Perkins DJ, Lambert CG. Using Machine Learning Imputed Outcomes to Assess Drug-Dependent Risk of Self-Harm in Patients with Bipolar Disorder: A Comparative Effectiveness Study. JMIR Ment Health. 2021 Apr 21;8(4):e24522. doi: 10.2196/24522.</citation>
    <PMID>33688834</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Christophe Gerard Lambert</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Oxcarbazepine</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Asenapine</mesh_term>
    <mesh_term>Perphenazine</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
    <mesh_term>Doxepin</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
    <mesh_term>Vilazodone Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This retrospective observational study makes use of MarketScan individual level patient data from Truven Health Analytics. The license terms for data access prohibit public dissemination of individual level patient data. The investigators will, however, make openly available the queries and analytic procedures required to reproduce the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

